Dovetail
Medical device design transfer readiness

Medical device design transfer readiness

For a medical device design transfer, review the connection between your selected design outputs, the instructions production will use and the evidence supporting the handoff. A document list helps you find files, but a readiness review should also expose revision mismatches, unresolved questions and the people responsible for deciding what happens next.

What should your design-transfer review answer?

Start with a defined handoff scope. Name the device configuration, manufacturing location, supplier involvement and activities you plan to transfer. Then ask whether the receiving functions can identify the controlled instructions and evidence relevant to that scope. A successful prototype alone does not answer those questions.

You might review an assembly operation first rather than treat the entire device as one transfer decision. Record what that review includes and what it leaves for another decision, such as packaging, servicing or a later manufacturing site. Without that boundary, a signature can look broader than the evidence behind it.

The worksheet below is a practical review aid, not a prescribed regulatory form or a complete compliance assessment. Adapt it to your device, quality management system and applicable requirements. Your responsible quality, engineering and manufacturing functions determine the evidence and approvals appropriate to the actual handoff.

Which US requirements should you check first?

The US Food and Drug Administration's Quality Management System Regulation, or QMSR, incorporates ISO 13485 into the device quality-system framework. Current 21 CFR 820.7 identifies the incorporated edition as ISO 13485:2016. Section 820.10(c) applies the design-and-development requirements to manufacturers of class II and class III devices and the specified class I devices. Do not assume every class I device has the same design-and-development obligations.

Use those current provisions to establish applicability with your regulatory lead. Do not rely on an older checklist that presents former section 820.30(h) as today's standalone transfer rule. Current Part 820 reserves sections 820.20 through 820.30 and directs applicable manufacturers to ISO 13485 through section 820.10.

There is useful context in FDA's 2024 final-rule response to Comment 31, pages 7507 to 7508. FDA explains that final design output forms the basis or starting point for the medical device file and describes that file as containing or referencing the procedures and specifications current on the manufacturing floor. That explanation supports examining the connection between design outputs and production documents. It does not make the worksheet here a legal requirement.

For an exact assessment of the transfer obligations within the incorporated standard, consult the applicable ISO text and qualified advice. This guide does not reproduce that clause or replace a device-specific review.

How can you build a useful evidence worksheet?

Take one selected design output and follow it into the documents the receiving function will actually use. Identify the revisions, the evidence relevant to the activity and any unresolved question. Keep document identifiers and links explicit enough that another reviewer can repeat the trace without guessing which copy you meant.

Review fieldWhat to recordQuestion it helps answer
Transfer scopeDevice configuration, site and activity under reviewWhat does this decision cover?
Selected design outputIdentifier, revision and relevant requirementWhich output are we handing over?
Production instructionControlled drawing, specification or instruction and revisionWhat will the receiving function use?
Supporting evidenceRelevant assessment or test record, revision and limitationsWhat supports this particular handoff?
Responsible functionsPreparing function, reviewer and decision authority under your QMSWho resolves the question and approves the outcome?
Open action and dispositionGap, assigned owner, next action and recorded decisionWhat still prevents a decision?

These fields are suggested working categories. They do not establish a universal evidence set, testing program or approval hierarchy. For example, a process may raise a validation question, but this worksheet cannot determine the answer without the process, device and applicable requirements.

Use your own supplier qualification record to inform supplier-related questions, and consult the supplier qualification guide for that separate assessment. Keep supplier approval and this specific transfer decision distinct. An approved supplier does not by itself resolve a mismatch between the drawing you reviewed and the instruction a production operator receives.

What does a revision mismatch look like in practice?

Consider a fictional manufacturer reviewing a fixture-assisted assembly operation. Engineering selects assembly drawing AD-014 revision C, but the proposed production instruction WI-022 revision B references revision B of that drawing. The available trial report also records revision B. The review cannot establish from those records alone whether the change to revision C affects the operation or the relevance of the trial evidence.

The useful outcome is an explicit question and a responsible owner, rather than a checked box saying that all three documents exist.

Evidence itemIllustrative review resultNext review action
AD-014 revision CSelected output for the scoped handoffEngineering identifies the change from revision B and its relevance
WI-022 revision BReferences the earlier drawing revisionManufacturing and quality review whether the instruction needs a controlled update
Trial report TR-009Records work against revision BResponsible functions assess whether the evidence supports the intended revision C operation
Transfer decisionEvidence relationship remains unresolvedRecord the gap, owner and decision after the assessment; do not describe this review as complete

Do not assume that every revision change demands a repeat test, or that a document update alone resolves the issue. In this example, the responsible functions first assess what changed and what the existing evidence can support. They then determine the action through the manufacturer's established processes.

A resolved record should show the rationale and the resulting controlled references. If the assessment supports using existing evidence, make that reasoning traceable. If further work is necessary, identify it and preserve the limit on what has actually been reviewed. This is an illustrative review method, not a validated release decision for a real device.

How should you close the review?

Close against the scope you defined, with the evidence available to the functions authorized to decide. A compact decision note can identify the reviewed configuration, document revisions, remaining actions and the rationale for the disposition. Separate a completed action from an accepted limitation so the next reader can tell them apart.

For internal tracking, you could use categories such as ready for the designated approval, further assessment needed and outside this review's scope. Those are practical labels, not regulatory statuses. None replaces the approvals your quality system requires, authorizes commercial distribution or establishes regulatory clearance.

Agree when the evidence trace should be revisited. A changed production instruction, manufacturing location or supplier may raise a question about the previous decision. Define how your existing change process identifies and assesses that question rather than inventing a separate approval route for this worksheet.

If your immediate problem is selecting a system to organize controlled work, use the eQMS guide for medical-device startups. If a later product complaint raises a manufacturing or design question, the US complaint-record guide addresses a different record and investigation decision. Neither guide replaces the transfer assessment.

Sources and further reading

Questions about design-transfer readiness

Check the scope of the evidence before making a decision.

In this guide, it is a practical review of the connection between a defined set of design outputs, controlled production instructions and supporting evidence. The worksheet helps identify unresolved questions and responsible functions. It is not a complete compliance assessment or a prescribed regulatory form.

No. Current 21 CFR 820.10(c) identifies class II and class III devices and specified class I devices for the design-and-development requirements. Confirm applicability for your device rather than applying an identical checklist to every class I manufacturer. 21 CFR 820.10(c)

Review its regulatory references before relying on it. Current Part 820 reserves sections 820.20 through 820.30, while section 820.10 directs applicable manufacturers to the incorporated ISO 13485 requirements. Useful practical questions in an older checklist do not make its old regulatory citation current. Current 21 CFR Part 820

This worksheet cannot establish a universal answer. Assess what changed, the scope and limitations of the existing evidence, and the applicable requirements through your established quality processes. Record the resulting rationale and any further work instead of assuming either automatic retesting or automatic acceptance.

No. It is a navigation and decision aid. FDA's response to Comment 31 in the 2024 final rule explains that final design output forms the starting point for the medical device file and that the file contains or references current manufacturing procedures and specifications. A worksheet does not replace the applicable documentation or approval requirements. FDA final rule, response to Comment 31, pages 7507 to 7508

Keep the handoff evidence easy to follow

A useful readiness review leaves the next reviewer with a defined scope, controlled references and an understandable decision. If you are evaluating a system to support your quality work, explore QMS Plus alongside the processes and evidence your team needs to manage.

About the author

Dr Spencer Todd is the CEO and co-founder of Dovetail, a regulatory partner for medical device companies. Before founding Dovetail, he spent years at the FDA and as a medical device consultant.